| Name | Title | Contact Details |
|---|
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Baxter International Inc. is a Fortune 500 American health care company with headquarters in Deerfield, Illinois.
Esschem is the worlds most respected manufacturer of specialty acrylic polymers and monomers for medical and cosmetic uses.
Natrol, Inc. subsidiary of Plethico Pharmaceuticals Limited is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Indago is developing smart surgical tools that enable physicians to focus on healthcare, not hardware. Our mission: to create the OR of the future.